Literature DB >> 22614887

Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.

Amit C Achhra1, Janaki Amin, Caroline Sabin, Haitao Chu, David Dunn, Lewis H Kuller, Joseph A Kovacs, David A Cooper, Sean Emery, Matthew G Law.   

Abstract

OBJECTIVE: To evaluate the change in categories of risk of death by adding D-dimer to conventional mortality risk factors.
DESIGN: Cohort study.
METHODS: Data on HIV-infected participants receiving standard combination antiretroviral therapy in two clinical trials (Evaluation of Subcutaneous Proleukin in a Randomized International Trial and Strategic Management of antiretroviral therapy), who had baseline D-dimer measured, were randomly split into two equal training and a validation datasets. A multivariable survival model was built using the training dataset and included only conventional mortality risk factors measured at baseline. D-dimer was added to create the comparison model. The level of reclassification of mortality risk, for those with at least 5-years of follow-up, was then assessed by tabulating mortality risk defined as low (≤2% predicted rate), moderate (2-5%) or high (>5%). Reclassification analyses were then repeated on the validation dataset.
RESULTS: The analysis population at baseline had a mean age of 43 years, median CD4(+) cell count of 535 cells/μl (IQR: 420-712), and 83% had HIV RNA of at least 500 copies/ml. In the training dataset (n=1946, 8939 person-years), there were 83 deaths at a rate of 0.93 per 100 person-years. Addition of D-dimer to the reference model resulted in 6% or fewer (P>0.05) being correctly reassigned, either up or down, to a new risk category, in both, training and validation datasets. The integrated discrimination improvement in training and validation datasets was 0.60% (P=0.084) and 0.45% (P=0.168), respectively.
CONCLUSION: In this relatively well population, at the given risk cutoffs, D-dimer appeared to only modestly improve the discernment of risk. Risk reclassification provides a method for assessing the clinical utility of biomarkers in HIV cohort studies.
© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614887      PMCID: PMC5516536          DOI: 10.1097/QAD.0b013e328355d659

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  40 in total

1.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

2.  Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology.

Authors:  P A Sakkinen; E M Macy; P W Callas; E S Cornell; T E Hayes; L H Kuller; R P Tracy
Journal:  Am J Epidemiol       Date:  1999-02-01       Impact factor: 4.897

3.  Use of reclassification for assessment of improved prediction: an empirical evaluation.

Authors:  Ioanna Tzoulaki; George Liberopoulos; John P A Ioannidis
Journal:  Int J Epidemiol       Date:  2011-02-16       Impact factor: 7.196

4.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ewout W Steyerberg
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

5.  Haemoglobin and anaemia in the SMART study.

Authors:  Amanda Mocroft; Alan R Lifson; Giota Touloumi; Jacqueline Neuhaus; Zoe Fox; Adrian Palfreeman; Michael J Vjecha; Sally Hodder; Stephane De Wit; Jens D Lundgren; Andrew N Phillips
Journal:  Antivir Ther       Date:  2011

6.  Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.

Authors:  Amanda Mocroft; Peter Reiss; Jacek Gasiorowski; Bruno Ledergerber; Justyna Kowalska; Antonio Chiesi; Jose Gatell; Aza Rakhmanova; Margaret Johnson; Ole Kirk; Jens Lundgren
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

7.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

8.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

9.  Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.

Authors:  Nancy R Cook; Paul M Ridker
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

10.  Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.

Authors:  Jeffrey A Tice; Steven R Cummings; Rebecca Smith-Bindman; Laura Ichikawa; William E Barlow; Karla Kerlikowske
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

View more
  5 in total

1.  Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy.

Authors:  A C Achhra; A Phillips; S Emery; R D MacArthur; H Furrer; S De Wit; M Losso; M G Law
Journal:  HIV Med       Date:  2015-05-11       Impact factor: 3.180

2.  The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.

Authors:  Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

3.  Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications.

Authors:  David Shasha; Bruce D Walker
Journal:  Front Immunol       Date:  2013-06-25       Impact factor: 7.561

4.  Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.

Authors:  Birgit Grund; Jason V Baker; Steven G Deeks; Julian Wolfson; Deborah Wentworth; Alessandro Cozzi-Lepri; Calvin J Cohen; Andrew Phillips; Jens D Lundgren; James D Neaton
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

5.  Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study.

Authors:  Daniel D Murray; Kazuo Suzuki; Matthew Law; Jonel Trebicka; Jacquie Neuhaus; Deborah Wentworth; Margaret Johnson; Michael J Vjecha; Anthony D Kelleher; Sean Emery
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.